Sarepta Therapeutics Inc
XMUN:AB3A
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Sarepta Therapeutics Inc
XMUN:AB3A
|
US |
|
Eclipx Group Ltd
ASX:ECX
|
AU |
|
C
|
CMOC Group Ltd
XMUN:D7N
|
CN |
|
E
|
Essential Utilities Inc
F:A2A
|
US |
|
Net Insight AB
STO:NETI B
|
SE |
|
A
|
AP Moeller - Maersk A/S
DUS:DP4B
|
DK |
|
CompuGroup Medical SE & Co KgaA
OTC:CMPVF
|
DE |
|
B
|
Banco Santander SA
SWB:BSD2
|
ES |
|
Z
|
Zijin Mining Group Co Ltd
XMUN:FJZ
|
CN |
|
P
|
Prodea Real Estate Investment Company SA
ATHEX:PRODEA
|
GR |
|
Holcim AG
SIX:HOLN
|
CH |
Wall St Price Targets
AB3A Price Targets Summary
Sarepta Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for
AB3A is 18.71 EUR with a low forecast of 4.18 EUR and a high forecast of 33.02 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is AB3A's stock price target?
Price Target
18.71
EUR
According to Wall Street analysts, the average 1-year price target for
AB3A is 18.71 EUR with a low forecast of 4.18 EUR and a high forecast of 33.02 EUR.
What is the Revenue forecast for Sarepta Therapeutics Inc?
Projected CAGR
-3%
Over the last 14 years, the compound annual growth rate for Revenue has been 32%. The projected CAGR for the next 8 years is -3%.